^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    FLT3 inhibitor

    Related drugs:
    3d
    VENP-A-QUI: A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patients ineligible for standard induction chemotherapy (2025-522979-29-00)
    P2/3, N=350, Recruiting, Fundacion PETHEMA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib)
    3d
    Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elzonris (tagraxofusp-erzs) • Vonjo (pacritinib)
    5d
    NCI-2020-05261: Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=58 --> 30
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation
    |
    azacitidine • Vanflyta (quizartinib)
    5d
    POSTPONE: Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Medical College of Wisconsin | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    Vonjo (pacritinib)
    9d
    PACIFICA: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov)
    P3, N=407, Active, not recruiting, Swedish Orphan Biovitrum | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Oct 2028
    Enrollment closed • Trial completion date
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • hydroxyurea
    10d
    CA011-023: A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) (clinicaltrials.gov)
    P1/2, N=216, Active, not recruiting, Bristol-Myers Squibb | N=108 --> 216
    Enrollment change
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib) • ezobresib (BMS-986158)
    11d
    HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML (clinicaltrials.gov)
    P3, N=324, Recruiting, Sunshine Lake Pharma Co., Ltd. | Trial completion date: Jun 2027 --> May 2028 | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • azacitidine • decitabine • idarubicin hydrochloride • fludarabine IV • clifutinib (HEC73543)
    12d
    A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants (clinicaltrials.gov)
    P1, N=80, Not yet recruiting, Sunshine Lake Pharma Co., Ltd. | Trial completion date: May 2026 --> May 2027 | Initiation date: Mar 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    clifutinib (HEC73543) • itraconazole • efavirenz
    13d
    Nintedanib Is a Potent FLT3 Inhibitor with Activity Against FLT3-ITD and Overcomes the Gatekeeper F691L Resistance Mutation in Acute Myeloid Leukemia. (PubMed, Eur J Pharmacol)
    In a Ba/F3 FLT3-ITD-F691L mouse model, nintedanib demonstrated superior anti-leukemic efficacy compared with gilteritinib and quizartinib. Furthermore, nintedanib potently inhibited primary AML blasts harboring FLT3-ITD while normal bone marrow remained intact. These findings identify nintedanib as a promising FLT3 inhibitor and support its further therapeutic investigation in FLT3-ITD-positive AML.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Vanflyta (quizartinib) • nintedanib
    15d
    Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    PLD-102
    17d
    A Randomized, Open-label, Positive-controlled, Parallel-grouped, Multicenter Phase III Clinical Trial on the Efficacy and Safety of Flonoltinib Maleate Tablets in Patients With Intermediate- or High-risk Myelofibrosis (ChiCTR2600118347)
    P3, N=105, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University; Chengdu
    New P3 trial
    |
    ZenFlonate (flonoltinib)
    18d
    Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia. (PubMed, Eur J Haematol)
    XY0206 exhibited a favorable safety profile and demonstrated potent antileukemic activity, particularly in FLT3mut+ R/R AML patients, supporting its further clinical development. Trial Registration: CTR20201214 (CDE); ClinicalTrials.gov ID: NCT04471064.
    Clinical • P1/2 data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    XY0206